{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:27:36Z","timestamp":1788532056769,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"New Round of Xuzhou \u00e2\u20ac\u0153Pengcheng Talent Program\u00e2\u20ac\u009d \u00e2\u20ac\u201c High-level Healthcare Talent Recruitment and Development Project","award":["2025TD06"],"award-info":[{"award-number":["2025TD06"]}]},{"name":"General Project of Xuzhou Health Commission","award":["XWKYH20240046"],"award-info":[{"award-number":["XWKYH20240046"]}]},{"name":"Shanghai Changjiang Delta Medical Innovation Life and Health Industry Foundation","award":["2025-YRDFHI-064"],"award-info":[{"award-number":["2025-YRDFHI-064"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Most patients with hormone receptor-positive breast cancer (BC) prefer endocrine therapy and chemotherapy. However, some HR+ BC patients often exhibit resistance to CDK4\/6 inhibitors and even undergo molecular subtyping changes during disease progression. Therefore, precise detection and treatment of these patients after disease progression are crucial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>In October 2021, a 51-year-old Chinese female (Han ethnicity) with a palpable mass in her left breast was diagnosed with HR+ BC. After endocrine therapy and CDK4\/6 inhibitor treatment, the patient\u2019s disease still progressed and transformed into triple-negative BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>\n                      Peripheral blood circulating tumor cells were isolated from the patient and performed targeted sequencing by using next-generation sequencing, revealing the presence of a\n                      <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                      mutation in the patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient\u2019s condition was effectively controlled after treatment with PI3K inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient\u2019s progression free survival was prolonged to 7 months after treatment with the PI3K inhibitor. All adverse reactions were tolerated after symptomatic treatment. Her adverse reactions remained tolerable until further progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>\n                      Our case fully demonstrates the importance of the early detection of\n                      <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                      mutations in treatment strategies. In addition, circulating tumor cells-targeted sequencing technology could be used for the concomitant diagnosis of advanced BC and evaluate gene mutations under treatment pressure.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048622","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:02:00Z","timestamp":1778896920000},"page":"e48622","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["PIK3CA mutation detection by circulating tumor cell sequencing guides the effective PI3K inhibitor treatment of a patient with hormone receptor-positive breast cancer transformed into triple-negative breast cancer: A case report"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6696-3800","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Xuzhou Hospital Affiliated to Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxu","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Xuzhou Hospital Affiliated to Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Xuzhou Hospital Affiliated to Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Xuzhou Hospital Affiliated to Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[{"name":"Nanjing RontiMed Laboratory Co., Ltd, Nanjing, Jiangsu, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[{"name":"The Second Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260904","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"1550988","DOI":"10.3389\/fimmu.2025.1550988","article-title":"Knowledge mapping of tumor microenvironment for breast cancer: a bibliometric analysis from 2014 to 2023.","volume":"16","author":"Jiang","year":"2025","journal-title":"Front Immunol"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","article-title":"Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.","volume":"2","author":"Clark","year":"1984","journal-title":"J Clin Oncol"},{"key":"R4-20260904","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.biochem.68.1.559","article-title":"Nuclear-receptor ligands and ligand-binding domains.","volume":"68","author":"Weatherman","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer.","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology.","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"1148792","DOI":"10.3389\/fcell.2023.1148792","article-title":"CDK4\/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective.","volume":"11","author":"Zhou","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer.","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R9-20260904","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer.","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"key":"R10-20260904","first-page":"113","article-title":"Guidelines on tests of PIK3CA mutation in breast cancer in China (2025 version).","volume":"54","year":"2025","journal-title":"Chin J Pathol"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences.","volume":"534","author":"Nik-Zainal","year":"2016","journal-title":"Nature"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1387\/ijdb.113421mb","article-title":"Developmental and cancer research on the mammary gland nowadays.","volume":"55","author":"Bracke","year":"2011","journal-title":"Int J Dev Biol"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","article-title":"Subtype switching in breast cancer brain metastases: a multicenter analysis.","volume":"22","author":"Hulsbergen","year":"2020","journal-title":"Neuro Oncol"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"1669741","DOI":"10.3389\/fgene.2025.1669741","article-title":"Single-cell transcriptomics in metastatic breast cancer: mapping tumor evolution and therapeutic resistance.","volume":"16","author":"Han","year":"2025","journal-title":"Front Genet"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/cancers17071102","article-title":"Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies.","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R16-20260904","first-page":"105","article-title":"Tumor heterogeneity: causes and consequences.","volume":"1805","author":"Marusyk","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer.","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours.","volume":"490","year":"2012","journal-title":"Nature"},{"key":"R19-20260904","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4161\/cbt.3.8.994","article-title":"The PIK3CA gene is mutated with high frequency in human breast cancers.","volume":"3","author":"Bachman","year":"2004","journal-title":"Cancer Biol Ther"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10549-007-9847-6","article-title":"Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.","volume":"112","author":"Zhang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"R21-20260904","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.","volume":"68","author":"Stemke-Hale","year":"2008","journal-title":"Cancer Res"},{"key":"R22-20260904","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","article-title":"Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.","volume":"13","author":"Miller","year":"2011","journal-title":"Breast Cancer Res"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-020-0846-y","article-title":"Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.","volume":"13","author":"Coussy","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R24-20260904","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.3390\/cells11162508","article-title":"PI3K\/AKT\/mTOR-targeted therapy for breast cancer.","volume":"11","author":"Zhu","year":"2022","journal-title":"Cells"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/jpm12111793","article-title":"PIK3CAMutations in breast cancer subtypes other than HR-Positive\/HER2-negative.","volume":"12","author":"Ascione","year":"2022","journal-title":"J Pers Med"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer.","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.","volume":"65","author":"Saal","year":"2005","journal-title":"Cancer Res"},{"key":"R28-20260904","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/2159-8290.CD-20-0553","article-title":"Triplet therapy with palbociclib, taselisib, and fulvestrant in PIK3CA-mutant breast cancer and doublet palbociclib and taselisib in pathway-mutant solid cancers.","volume":"11","author":"Pascual","year":"2021","journal-title":"Cancer Discov"},{"key":"R29-20260904","first-page":"101805","article-title":"PIK3CA mutation analysis in circulating tumor cells of patients with hormone receptor positive metastatic breast cancer.","volume":"39","author":"Marino","year":"2024","journal-title":"Biochem Biophys Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:02:53Z","timestamp":1788530573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":29,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048622","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2026-03-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}